Cargando…
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies
BACKGROUND: Clinical evidence regarding intestinal Behçet’s disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor...
Autores principales: | Hisamatsu, Tadakazu, Ueno, Fumiaki, Matsumoto, Takayuki, Kobayashi, Kiyonori, Koganei, Kazutaka, Kunisaki, Reiko, Hirai, Fumihito, Nagahori, Masakazu, Matsushita, Mitsunobu, Kobayashi, Kenji, Kishimoto, Mitsumasa, Takeno, Mitsuhiro, Tanaka, Masanori, Inoue, Nagamu, Hibi, Toshifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895195/ https://www.ncbi.nlm.nih.gov/pubmed/23955155 http://dx.doi.org/10.1007/s00535-013-0872-4 |
Ejemplares similares
-
Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants
por: Watanabe, Kenji, et al.
Publicado: (2020) -
Evidence-based clinical practice guidelines for inflammatory bowel disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018) -
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
por: Inoue, Nagamu, et al.
Publicado: (2017) -
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018) -
Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
por: Kobayashi, Taku, et al.
Publicado: (2019)